

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex: 53 years Female

Specimen Collected: 11-Mar-24 08:50

<b>Porphobilinogen Quantitative Urine</b>	<b> Received: 11-Mar-24 08:50</b>	<b>Report/Verified: 11-Mar-24 08:53</b>
---	-----------------------------------	---

<b>Procedure</b>	<b>Result</b>	<b>Units</b>	<b>Reference Interval</b>
Hours Collected	24 <sup>f1</sup>	hr	
Total Volume	100	mL	
Creatinine, Urine -per volume	1000	mg/dL	
Creatinine, Urine -per 24h	1000	mg/d	[500-1400]
Porphobilinogen (PBG), Urine -per volume	100.1 <sup>i1</sup>	umol/L	
Porphobilinogen, Urine -per 24h	<b>10.0 #</b>	umol/d	[0.4-1.5]
Porphobilinogen, Urine -ratio to CRT	<b>1.1 #</b>	mmol/mol CRT	[0.0-0.2]
Porphobilinogen Interpretation	See Note <sup>i2</sup>		

**Result Footnote**

f1: Hours Collected

Per 24h calculations are provided to aid interpretation for collections with a duration of 24 hours and an average daily urine volume. For specimens with notable deviations in collection time or volume, ratios of analytes to a corresponding urine creatinine concentration may assist in result interpretation.

**Test Information**

i1: Porphobilinogen (PBG), Urine -per volume

i2: Porphobilinogen Interpretation

INTERPRETIVE INFORMATION: Porphobilinogen Interpretation

**Porphobilinogen (PBG), Urine**

Results for random urine specimens are normalized to creatinine (CRT) concentration and reported as a ratio of amounts (millimoles of PBG/mole of creatinine). Porphobilinogen (PBG) in a random urine specimen is used to evaluate an attack of acute porphyria. Slight increases in urinary PBG are associated with acute porphyrias other than acute intermittent porphyria (AIP) and may indicate a resolving or treated acute porphyria. Urinary PBG in excess of two times the upper reference limit is consistent with acute porphyria.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

**Unless otherwise indicated, testing performed at:****ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 24-071-900015**Report Request ID:** 19127597**Printed:** 11-Mar-24 08:55

Page 1 of 1